We look at a COVID-19 remedy called monoclonal antibodies—or MAB for short. They are basically antibodies made in a lab and they can potentially be life-saving. But this treatment is in short supply in many areas in the U.S. including but not limited to Connecticut, Nevada, and Ohio. NTD spoke with CEO Michael Einhorn who runs Dealmed. He says there are a lot of reasons for the shortage of MABs, but he says government intervention is a main driver.
Government Control Led to Lack of COVID-19 Remedy: CEO
By Kevin Hogan
Sign up for NTD Daily
What you need to know, summarized in one email.
Stay informed with accurate news you can trust.
Stay informed with accurate news you can trust.
Success! You are now subscribed.
By registering for the newsletter, you agree to the Privacy Policy.